Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00332215 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.
A Phase 1 study, sponsored by University of Minnesota.
- Terminated
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT00332215 is a Phase 1 study that was terminated before completion, run by University of Minnesota. The registered enrollment target is 70 participants.
The verdict
NCT00332215, a Phase 1 study, was terminated before completion, sponsored by University of Minnesota.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the safety of inhaled sodium pyruvate in people with Cystic Fibrosis (CF). Further, to determine whether inhaled sodium pyruvate will improve lung function, as determined by FEV1, or reduce inflammatory markers in induced sputum of people with CF.
Interventions
- DRUG Inhaled Sodium Pyruvate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2006-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00332215
The ClinicalTrials.gov registry entry for NCT00332215 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Inhaled Sodium Pyruvate is the first listed.
NCT00332215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00332215 about?
NCT00332215 is a clinical study titled "A Phase I Study of Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.". The primary objective of this study is to assess the safety of inhaled sodium pyruvate in people with Cystic Fibrosis (CF). Further, to determine whether inhaled sodium pyruvate will improve lung function, as determined by FEV1, or reduce inflammatory markers in induced sputum of people with CF.
What is the current status of trial NCT00332215?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2006-02.
What interventions are being tested in trial NCT00332215?
The interventions under investigation include: Inhaled Sodium Pyruvate (DRUG).
Who is sponsoring clinical trial NCT00332215?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.